SLC2A3 and pancreatic neoplasm: In pancreatic cancer cells, knockdown of SIRT7 resulted in increased expression of glucose transporter protein 3 (GLUT3) as well as increased levels of H3K122succ, which in turn led to pancreatic cancer cells being more sensitive to gemcitabine.